SUBSCRIBE
SUBSCRIBE

Ipsen Biopharmaceuticals, Inc.

NEWS
Biotech Beach
The Day In Review: Tercica, Inc. And Ipsen Sign Cross-License Deal
July 19, 2006
 · 
1 min read
Business
Ipsen Joins Pfizer In Breast Cancer Trials
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Genetown
Ipsen: New Patient-Reported Data Demonstrated High Satisfaction Levels and Fewer Patients Reporting Injection-site Pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide)
March 8, 2022
 · 
14 min read
Drug Development
Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial
February 15, 2022
 · 
14 min read
Business
Ipsen Presents Strong Full-Year 2021 Results and Enters Into Exclusive Negotiations to Divest Its Consumer Healthcare Business
February 11, 2022
 · 
43 min read
Policy
Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
January 24, 2022
 · 
7 min read
Business
Ipsen Nominates Karen Witts as New Independent Board Member
January 21, 2022
 · 
6 min read
Business
Ipsen Delivers Strong Sales Growth for the First Nine Months and Improves Its Full-Year Guidance
October 21, 2021
 · 
16 min read
Drug Development
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
October 18, 2021
 · 
8 min read
Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer
September 18, 2021
 · 
19 min read
Policy
Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-submit Following Additional Data Analyses
August 13, 2021
 · 
11 min read
Business
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
August 2, 2021
 · 
14 min read
Load More